Alvotech · NASDAQ:ALVO
Alvotech — SPAC Merger (March 2022)
84 slides from Alvotech's SPAC merger presentation, Mar 23, 2022
Slide 1: Analyst Day March 2022
Filed by Alvotech Lux Holdings S.A.S. (Commission File No. 333-261773) Pursuant to Rule 425 under the Securities Act of 1933 And Deemed Filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Oaktree Acquisition Corp. II ANALYST DAY MARCH 2022
Slide 2: Important disclaimer
This investor presentation (this “Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between Oaktree Acquisition Corp. II (“SPAC”) and Alvotech Holdings S.A. (tog
Slide 3: Use of Projections; Industry and Market Data
Use of Projections This Presentation contains financial forecasts with respect to the Company’s projected financial results, including Revenue and Adjusted EBITDA, for the Company's fiscal years 2021, 2025 and from 2025-2030. The Company's independent auditors have not audited, reviewed, compiled or
Slide 4: Today's Agenda
Today’s Agenda Robert Wessman Zaid Pardesi Opening Remarks & Introduction to Oaktree and Alvotech Alvotech founder & Chief Financial 09:00AM – 09:15AM Chairman Officer and Head of M&A of OACB Mark Levick Ming Li Biosimilars Background and Opportunity 09:15AM – 09:40AM Chief Executive Chief Strategy
Slide 5: Alvotech: Compelling Platform Providing Pure-Play Access To The Rapidly Growing Biosimilar Market
Alvotech: Compelling Platform Providing Pure-Play Access To The Rapidly Growing Biosimilar Market • Pioneers in biosimilar development with a track record of obtaining PROVEN LEADERSHIP TEAM marketing authorization for 17 biosimilars and 8 originator biologics 1 globally • Significant acceleration o
Slide 6: Alvotech Is Founder Robert Wessman's Third Platform In The Pharma Sector
Alvotech Is Founder Robert Wessman’s Third Platform In The Pharma Sector Robert Wessman Background Revenue Increase Under Wessman Leadership $ in millions Past platforms that Current Platform Seasoned pharma executive that have created billions in Alvotech has led 50+ strategic acquisitions in value
Slide 7: This is Alvotech
This is Alvotech 7
Slide 8: Growth Platform Ready To Be Deployed Having Been Built Over 9 Years
Growth Platform Ready To Be Deployed Having Been Built (3) Over 9 Years With ~$1 Billion Of Invested Capital Build Foundation Commercial Readiness Deploy Platform (2013-2017) (2018-2020) (2021-2025+) ✓ Established global distribution • Existing pipeline matures and new ✓ Set 10-year platform vision
Slide 9: Alvotech at a Glance
Alvotech Partners Alvotech at a Glance – Full-Scale, Pure-play Biosimilar Developer and Manufacturer with Global Commercial Capabilities A 8 pipeline candidates with › Purpose-built and in-house R&D platform, solely focused $85Bn+ sales potential on the development of biosimilar products R&D ~720 pe
Slide 10: Proven & Highly Experienced Management Team
Proven & Highly Experienced Management Team Having Successfully Developed 17 Biosimilars 20 20 20 15 20 MARK LEVICK, JOSEPH E. JOEL MORALES, ANIL OKAY, MING LI, MCCLELLAN, Chief Chief Executive Chief Financial Chief Strategy Commercial Officer Chief Scientific Officer Officer Officer Officer 20 15 2
Slide 11: Highly Aligned Social And Corporate Purpose
Highly Aligned Social And Corporate Purpose Corporate Purpose Social Purpose Alvotech is dedicated to Alvotech aims to be the making patients’ lives leading supplier of better by improving access biosimilars globally to affordable biosimilar medicines and the sustainability Our corporate purpose is
Slide 12: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY
Slide 13: Opportune Timing for Industry and Alvotech
Opportune Timing for Industry and Alvotech • Established regulatory pathway to market including interchangeability for the U.S. market Biosimilar • Significant number of biologic LoEs on the Market horizon • Global biosimilars market estimated to grow to Evolution $79 billion in 2026 (17% CAGR from
Slide 14: Biosimilar Development Holds Less Risk and Complexity than Originator Biologics
Biosimilar Development Holds Less Risk and Complexity than Originator Biologics, and Significantly More Complexity and Barriers to Entry Than Generics Originator Biologics Biosimilars Generics (1) (2) (3) (5) Development Costs $2.6Bn $100-200MM $1-2MM (2) (3) (6) PoS Low Moderate to high High Develo
Slide 15: Biologic Approvals Are Increasing Rapidly
Biologic Approvals Are Increasing Rapidly, A Leading Indicator For The Biosimilar Opportunity Originator Biologics Market is Large and Growing Increasing US biologic medicine approvals… …is driving expectations for rapidly growing $ sales Number of FDA Approvals Total Global Biologics Market Size ($
Slide 16: Biosimilars Are Entering A Period Of Substantial Growth
Biosimilars Are Entering A Period Of Substantial Growth As Early Biologics Lose Patent Protection (3) Opportunity for Biosimilars to Expand Patient Access Biosimilars Adoption Growing Rapidly • High price of biologic medicines is placing a significant cost Total Global Biosimilar Market Size ($Bn) b
Slide 17: US Biosimilar Regulatory Pathway has Matured with 30+ Approved Products
US Biosimilar Regulatory Pathway has Matured with 30+ Approved Products ~Early 2000s 2014 March 2020 2018 First biosimilar First biosimilar filing Deadline to transition Launched Biosimilars Key Highlights programs started utilizing the certain biologics Action Plan abbreviated applications from NDA
Slide 18: US Biosimilar Market Showing Rapid Uptake With Modest Price Erosion
US Biosimilar Market Showing Rapid Uptake With Modest Price Erosion (1) (2) Biosimilar Uptake of Selected Products in US Market Originator and Biosimilar WAC Price Difference in US Total Biosimilar share (%) (as of October 2021) Percentage difference in average WAC of biosimilars and originator prod
Slide 19: Interchangeability May Enhance Speed Of Biosimilar Adoption
Interchangeability May Enhance Speed Of Biosimilar Adoption And Growth › Interchangeable designation in the US allows for substitution without (1) authorization by the prescribing physician ‒ Pharmacists can substitute the interchangeable biosimilar for the originator without approval ‒ Interchangea
Slide 20: EU Has Pioneered the Regulation of Biosimilars
EU Has Pioneered the Regulation of Biosimilars and Has 80+ Approved Biosimilars Early 2000s 2005 2007 2015 First biosimilar EMA publishes EMA provides EMA provides revised Key Highlights programs guidelines on comparability general guidelines on started biosimilars guidelines for biosimilars and rev
Slide 21: EU Biosimilar Market Overview
EU Biosimilar Market Overview (1) Biosimilar Uptake of Selected Products in EU Market EU Market Key Trends Biosimilar market share based on Standard Units including all available dosage strengths (as of Nov 2021) • Europe was an early adopter of biosimilars and is the most mature biosimilar market g
Slide 22: Competing Priorities Created an Opportunity for Biosimilar Focused Companies
Competing Priorities for Players, has Created an Opportunity for Biosimilar Focused Companies to Capture Growth Limited/Reduced Biosimilar Emphasis Pure-Play Key Highlights Biosimilar Focus within Broader Portfolio Biosimilar Focus ▪ Requires scale to play in biosimilars ▪ Biosimilar portfolios have
Slide 23: Benefits of a Core Focus Strategy on Biosimilars
Benefits of a Core Focus Strategy on Biosimilars Aligned Corporate Purpose ✓ › Mission driven purpose motivates and attracts high quality team › Provides pure-play exposure in a fast-growing market with limited true comps › Provides unique ESG characteristics Nimble and Adaptable ✓ › Flexibility to
Slide 24: ame se ay
ame se ay
Slide 25: Purpose-Built Biosimilar Platform
PURPOSE-BUILT BIOSIMILAR PLATFORM
Slide 26: Strategically Developed Platform Designed To Maximize Quality, Cost Containment And Efficiency
Strategically Developed Platform Designed To Maximize Quality, Cost Containment And Efficiency To Market PLATFORM ELEMENT ALVOTECH APPROACH Global end-to-end R&D platform spanning six locations with rigorous quality focus designed to de-risk development early and drive efficient advancement RESEARCH
Slide 27: R&D Process Designed To Optimize Development Outcomes
R&D Process Designed To Optimize Development Outcomes, While Balancing Time And Cost Focus Approach • Prioritize analytical similarity early in programs to de-risk development programs Maximize • Rigorously align global development strategies with global regulatory authorities to Development Success
Slide 28: Global Operating Footprint With Differentiated Biosimilar Capabilities
Global Operating Footprint With Differentiated Biosimilar Capabilities R&D Focused Sites JULICH SITE Cell line, media, process, and functional assay development proficiency HANOVER SITE Expertise in glycoprotein characterization methods and analyses VIRGINIA SITE Regulatory, government affairs, and
Slide 29: Extensive Manufacturing Capacity Located in Iceland
Extensive Manufacturing Capacity Located in Iceland Key Features Technology & Capabilities 2 • Approximately ~275,000ft facility (inclusive of ongoing expansion) with existing 4- (1) wall drug substance capacity to support pipeline through 2030 Capacity and Scalability ✓ • Commercial product manufac
Slide 30: Reykjavik Facility Expansion
Reykjavik Facility Existing Facility Expansion 2 2 ~140,000 ft ~135,000 ft 2 • Drug product expansion and redundancy (~20,000ft ) • Two “ballroom” drug substance areas with fed batch and perfusion 2 capabilities (~30,000ft ) 2 • Warehousing Expansion (~10,000ft ) 2 • Drug Product fill finish capacit
Slide 31: Global Commercial Partner Network
GLOBAL COMMERCIAL PARTNER NETWORK
Slide 32: Network Of High-Quality Regional Partners Provides Global Commercial Reach
Network Of High-Quality Regional Partners Provides Global Commercial Reach Alvotech’s Partner Partnered Territories Selection Criteria P Strategic Positioning Track record of success in local market SVALBARD (NORWAY) P Shared Risk Dynamic GREENLAND Structurally aligned incentives P Attractive Econom
Slide 33: Benefits of Global Commercial Partnerships
Benefits of Global Commercial Partnerships Accelerated Sales through Local Expertise › Commercial partners have established distribution networks, enabling rapid commercialization › Go-to-market strategy varies significantly across global markets; local know-how and brand awareness mitigates launch
Slide 34: Global Reach Through Partnerships
Global Reach Through Partnerships 34
Slide 35: Key Regional Partners Have Committed Up To $1.15Bn In Potential License Fees
Key Regional Partners Have Committed Up To $1.15Bn In Potential License Fees (~$950MM Outstanding) 2021A Licensed Alvotech Geographic 2021A Licensed Alvotech Geographic Partner Partner Partner Rev Products Rights Partner Rev Products Rights Australia, New (3) Zealand, South $2.8Bn 5 Africa US $15.9B
Slide 36: Key Aspects of Our Partnership Model
Key Aspects of Our Partnership Model Mutually Beneficial Structure › Commercial partnership agreements are strategic and mutually exclusive with long-term commitments for multiple products Scope of Work Leverages Core Capabilities › Partners are responsible for all commercialization activities and r
Slide 37: ame se ay
ame se ay
Slide 38: Diverse Pipeline With Significant TAM
DIVERSE PIPELINE WITH SIGNIFICANT TAM
Slide 39: Rigorous Approach To Constructing An Attractive Biosimilar Portfolio
Rigorous Approach To Strategically Constructing An Attractive Biosimilar Portfolio Potential Ways to Differentiate › Identify early, underappreciated originator markets Market Intel › Anticipate originator strategies and adapt Differentiation accordingly Commercial › Portfolio offerings and brand aw
Slide 40: Strategically Constructed Pipeline Of Biosimilars Representing $85Bn+ TAM
Strategically Constructed Pipeline Of Biosimilars Representing $85Bn+ TAM Alvotech’s Current Biosimilar Pipeline – Global Peak Branded Sales of Originator Branded Biologics $30.0Bn $86.2Bn $3.6Bn $3.7Bn $6.7Bn Future Growth $10.3Bn Market growth $10.8Bn Additional internal $21.2Bn programs - platfor
Slide 41: AVT02: Adalimumab Market Overview
AVT02: Adalimumab Market Overview Humira® TRx by Concentration Market Context ▪ Initial market for Humira was solely in the low Alvotech concentration is one of the few players addressing ▪ High concentration has aided the recent ~83%+ of market commercial success of the product o Improved pharmacok
Slide 42: AVT02: Multiple Points Of Differentiation
AVT02: Multiple Points Of Differentiation, Including High Concentration And Potential Interchangeability Program Status Alvotech Strategy ® Branded Biologic Humira • High concentration: One of the few known programs in (Generic Name) (Adalimumab) development with the high concentration (100mg/ml), ®
Slide 43: AVT02: Devices Used in Chronic Therapies are Important
AVT02: Devices Used in Chronic Therapies are Important Designed with Ergonomic Use in Mind Sturdy, oval design, and latex-free, solid Visual indicator when the construction for a substantial feel in hand injection is complete Soft, wide, textured grip for easy handling Lock-out feature after injecti
Slide 44: AVT02: Competitive Landscape Overview
AVT02: Competitive Landscape Overview Product information US Biosimilar Launch Status Interchangeability Manufacturer / Expected Launch Switching Program Approval Status Timing / Notes Marketer Date Study • Aim to be the first interchangeable, high concentration product at launch Alvotech / (1) (1)
Slide 45: AVT04: Stelara is a Rapidly Growing Product Ripe For Biosimilar Entry
AVT04: Stelara® is a Rapidly Growing Product Ripe For Biosimilar Entry Due To High Price Point (1) Historical and Projected Stelara® Sales ($Bn) Market Context 10.0 (2)▪ Stelara continues to increase revenue with double digit Stelara® Annual Cost of Treatment: $144,000 $9.4 YoY growth 9.0 nd rd ▪ At
Slide 46: AVT04: A Highly Differentiated Approach to a Stelara Biosimilar
AVT04: A Highly Differentiated Approach to a Stelara® Biosimilar Program Status Alvotech Strategy ® Branded Biologic Stelara • SP2/0 Host Line: Manufactured using same host cell line (Generic Name) (Ustekinumab) as Stelara® o SP2/0 host cell line allows for more efficient Originator Johnson & Johnso
Slide 47: AVT04: Competitive Landscape Overview
AVT04: Competitive Landscape Overview ▪ AVT04 is one of few known SP2/0 cell line based programs Product information US EU o SP2/0 cell line facilitates higher levels of sialic acid on Commercial Program Developer Commercial Partner the monoclonal antibody; high levels of sialic acid are Partner ass
Slide 48: AVT03: Denosumab Market Overview
AVT03: Denosumab Market Overview Historical and Projected Prolia® and XGEVA® Sales ($Bn) Market Context ▪ Prolia and Xgeva continue to experience attractive sales $5.8 growth as well as favorable pricing dynamics ’17A-’21A CAGR: 11% ▪ Growth for these products is expected to continue as the $5.2 $5.
Slide 49: AVT03: Novel Formulation for Denosumab
AVT03: Novel Formulation for Denosumab Program Status Alvotech Strategy Branded Biologic Prolia® and XGEVA® • Production consistency: Both the reference product as (Generic Name) (Denosumab) well as our proposed biosimilar AVT03, are produced in recombinant Chinese hamster ovary cells Originator Amg
Slide 50: AVT05: Golimumab Market Overview
AVT05: Golimumab Market Overview Historical and Projected Simponi® Sales ($Bn) Market Context ▪ Simponi (Golimumab) is an anti-TNF, the same class of ’17A-’21A CAGR: 5% therapeutic as Humira $3.6 $3.5 ▪ Simponi has a once-monthly formulation which is a $3.4 $3.3 differentiator among other anti-TNFs
Slide 51: AVT05: Only Known SP2/0 Cell-Line Based Program
AVT05: Only Known SP2/0 Cell-Line Based Program Alvotech Program Program Status AVT05 Alvotech Strategy Branded Biologic Simponi® • Interchangeability: Only publicly disclosed golimumab (Generic Name) (Golimumab) biosimilar program to be seeking the interchangeability designation Originator Johnson
Slide 52: AVT23: BiosanaPharma Agreement Overview
AVT23: BiosanaPharma Agreement Overview On February 2, 2022, Alvotech and BiosanaPharma entered into an exclusive global licensing agreement to co-develop AVT23 AVT23 Overview 3C Technology Platform ▪ AVT23 (aka BP001) is a late-stage biosimilar candidate for Xolair ▪ High productivity, flexible, sm
Slide 53: AVT23: Omalizumab Market Overview
AVT23: Omalizumab Market Overview Historical and Projected Xolair® Sales ($Bn) Market Context ▪ High physician familiarity and levels of experience with ’17A-’21A CAGR: 7% Xolair’s biologic class (e.g. IgE binding) $3.6 $3.3▪ Remains competitive against new entrants; with $3.2 reported US growth of
Slide 54: AVT23: Attractive Manufacturing Process for Omalizumab
AVT23: Attractive Manufacturing Process for Omalizumab Alvotech Program Program StatusXolair® Alvotech Strategy ® Branded Biologic Xolair ▪ Leverages the advancements made by Biosana utilizing (Generic Name) (Omalizumab) their proprietary 3C manufacturing technology o Highly efficient process with h
Slide 55: AVT06: Aflibercept Market Overview
AVT06: Aflibercept Market Overview Historical and Projected Eylea® Sales ($Bn) Market Context ▪ Eylea continues to be a leading ophthalmology product, ’17A-’21A CAGR: 12% with attractive market share across all approved $9.9 indications ▪ Full year 2021 Eylea US net sales increased 17% versus $8.4 2
Slide 56: AVT06: Compelling Formulation for Eylea (Aflibercept)
® AVT06: Compelling Formulation for Eylea (Aflibercept) Alvotech Program Program Status AVT06 Alvotech Strategy ® Branded Biologic Eylea • Vial and PFS offering in development: Matching the (Generic Name) (Aflibercept) innovator with both of the dosage forms available in the market Originator Regene
Slide 57: ame se ay
ame se ay
Slide 58: Attractive Financial Profile
ATTRACTIVE FINANCIAL PROFILE
Slide 59: Financial Forecast Overview
Financial Forecast Overview Overview Basis of • All financials are presented on an International Financial Reporting Standards (IFRS) basis of accounting Presentation • Detailed product-level in-market revenue build based on estimated penetration and pricing discount relative to originators Risk Adj
Slide 60: Attractive Revenue Potential As Products Commercialize
Attractive Revenue Potential As Products Commercialize Risk Adjusted Revenue Commentary $ in millions 2022-2025 • Milestones: ongoing payments Long-term from commercial partners that help growth offset R&D costs potential High single digit • Programs: 5 launched products growth expected by 2025 Pre-
Slide 61: Leverageable Business Model Designed To Produce Attractive Margins
Leverageable Business Model Designed To Produce Attractive Margins That Can Expand As The Platform Scales Illustrative Adjusted EBITDA Potential Commentary $ in millions Margin Profile Enabled by: • Portfolio selection focus on high Long-term value reference products dollar and margin • Milestone re
Slide 62: Financial Guidance Summary (Risk Adjusted)
Financial Guidance Summary (Risk Adjusted) 2021A (unaudited) 2022E 2025E 2025E – 2030E $ millions (1) (2) Product Revenue $0 $25 – $75 85% of total revenue (1) (3) 15% of total revenue Milestone Revenue $40 $60 – $80 (Cumulative $470MM+ from ’23E – ‘25E) High single-digit (1) Total Alvotech Revenue
Slide 63: Additional Opportunities Beyond The Financial Forecast
Additional Opportunities Beyond The Financial Forecast Conservative Baseline Projections Omit Numerous Opportunities For Upside Potential upside Earnings Revenue from In-licensing of driven by further contribution additional R&D external differentiation from China joint programs as programs from ven
Slide 64: Transaction Summary
alvotech ij i TRANSACTION SUMMARY
Slide 65: Highly Aligned Transaction Structure With 100% Rollover By Existing Shareholders
Highly Aligned Transaction Structure With 100% Rollover By Existing Shareholders Transaction Overview Illustrative Pro Forma Valuation ($mm) • Oaktree Acquisition Corp. II (NYSE: “OACB”) to combine with Alvotech at an Share Price $10.00 implied $1.8 billion pre-money equity value and a $2.25 billion
Slide 66: Well-Positioned, Pure-Play Biosimilars Platform
Well-Positioned, Pure-Play Biosimilars Platform Adjacent, Less Comparable Most Comparable (1) Listing Location US India US / Iceland South Korea South Korea (2) Structure Public Subsidiary Public Public Subsidiary Primary Biosimilar Focus ûPPPP Biosimilars R&D PPPPP Biosimilar Manufacturing ûPPPP Gl
Slide 67: Well-Positioned, Pure-Play Biosimilars Platform (Cont'd)
Well-Positioned, Pure-Play Biosimilars Platform (Cont’d) Key Pure-Play Listed Comparable (3) (4) (Parent) (Parent) 86.2 69.9 67.2 56.5 56.2 (2) 21.3 (6) Total Enterprise Value ($Bn) $1.0 $5.8 $2.3 $19.0 $39.3 (7) EV / NTM EBITDA N/M 17.5x N/A 22.3x 60.3x ’22E – ’25E Revenue CAGR 43% N/A >70% 7% 17%
Slide 68: Recent Biosimilar Transactions Support Valuation
Recent Biosimilar Transactions Support Valuation Samsung Biologics / Biogen Biosimilar JV Stake 17.0x ▪ Samsung was captive buyer through the ~50-50 JV with Biogen, limiting ability to extrapolate implied valuation/multiple ▪ Ongoing commercial relationship for distribution of current products with
Slide 69: Transaction Represents An Attractive Entry Point
Transaction Represents An Attractive Entry Point Transaction Value Today Illustrative Current Value Illustrative Future Value ($Bn) Meaningful upside $9.6 potential from transaction value and illustrative current value $7.2 Current EV represents ~45-60% discount to $5.8 illustrative current value $4
Slide 70: ame se ay
ame se ay
Slide 71: Alvotech: A Differentiated Global Biosimilars Company
Alvotech: A Differentiated Global Biosimilars Company PROVEN LEADERSHIP TEAM 1 SIGNIFICANT MARKET OPPORTUNITY 2 PURPOSE-BUILT BIOSIMILAR PLATFORM 3 GLOBAL COMMERCIAL PARTNER NETWORK 4 5 DIVERSE PIPELINE WITH SIGNIFICANT TAM ATTRACTIVE FINANCIAL PROFILE 6 71
Slide 72: Appendix: Select Management Team Biographies
APPENDIX SELECT MANAGEMENT TEAM BIOGRAPHIES
Slide 73: Highly Experienced Leadership Team
Highly Experienced Leadership Team 20 20 15 20 20 MARK LEVICK, JOSEPH E. JOEL MORALES, ANIL OKAY, MING LI, MCCLELLAN, Chief Chief Executive Chief Financial Chief Strategy Commercial Officer Chief Scientific Officer Officer Officer Officer • 15 years of industry • 20 years of industry • 20 years of i
Slide 74: Highly Experienced Leadership Team (Cont'd)
Highly Experienced Leadership Team (Cont’d) 20 15 15 20 29 PHILIP TANYA ZHAROV, SEAN GASKELL, REEM MALKI ANDREW ROBERTS, CARAMANICA, Chief Technical Deputy CEO Chief Quality Chief Portfolio Officer Chief IP Counsel, Officer Officer Deputy General Counsel • 15 years of industry • 20 years of industry
Slide 75: Appendix: Biosimilar Background Information
APPENDIX BIOSIMILAR BACKGROUND INFORMATION
Slide 76: Biosimilars Are Highly Comparable To Biologics
Biosimilars Are Highly Comparable To Biologics, An Important Class Of Medicine BIOLOGIC BIOSIMILAR Development Path • Proof of quality and analytical similarity • Pharmacokinetic bioequivalence • Clinical data showing comparable safety and efficacy • Support pharmacy substitution and interchangeabil
Slide 77: Regulatory Definition Of Biosimilars
Regulatory Definition Of Biosimilars A biosimilar is a biologic medicinal product that contains a version of the active substance of an already authorized original biologic medicinal product (reference medicinal product). A biosimilar demonstrates similarity to the reference medicinal product in ter
Slide 78: Key Stages And Milestones Of Biosimilar Development
Key Stages And Milestones Of Biosimilar Development 1 2 3 4 Manufacturing / Analytics Early Phase Pre-Clinical Submission Development Development & Approval PK/PD Study Pilot & GMP Mfg. Cell Line Process Confirmatory Patient Study • Project selection criteria include • Confirm high quality drug • Ex
Slide 79: Appendix: Additional Product Background
APPENDIX Additional Product Background
Slide 80: AVT02: Global Program Included 1500+ Subjects
AVT02: Global Program Included 1500+ Subjects Subjects (1) Study Overview Milestones Enrolled ® • 3-arm parallel study of AVT02 compared to EU-Humira and • Enrollment completed in December 2019 ® US-Humira in healthy adult subjects PK Similarity Study 390 • Study met its primary endpoints for all es
Slide 81: AVT02: Successful Switching Study Can Support Interchangeable Designation
AVT02: Successful AVT02-GL-302 Switching Study Can Support Potential Approval As Interchangeable Product In the US Subject study Participation = 52 Weeks SCREENING LEAD-IN PERIOD: OPEN LABEL TREATMENT SWITCHING MODULE: DOUBLE BLIND TREATMENT OPTIONAL EXTENSION PHASE: OPEN LABEL TREATMENT STAGE-1: OP
Slide 82: Appendix: CCHT Joint Venture
Avalvotech APPENDIX CCHT JOINT VENTURE
Slide 83: Alvotech's China Commercial Partner: Yangtze River Pharmaceutical Group
Alvotech’s China Commercial Partner: Yangtze River Pharmaceutical Group YRPG Network & Infrastructure China Coverage Overview › YRPG has well-established distribution networks cover all districts nationally with more than 10,000 hospitals, 1,200 chain stores, and 20,000 retails, which account for ~8
Slide 84: Risk factors
Carefully consider the following risk factors, among others that will be contained in (or incorporated by reference into) the proxy statement/prospectus, related to Alvotech’s business, reputation, financial condition, results of operations, revenue and the future prospects if the business combinati